Myostatin inhibitor comprising extracellular water-soluble domains of DLK1 as active ingredient
First Claim
1. A method for treating a myostatin-related disease, comprising administering to a subject having a myostatin-related disease, an extracellular water-soluble domain of a delta-like 1 homolog (DLK1) comprising the sequence of SEQ ID NO:
- 34, a fragment of the extracellular water-soluble domain of DLK1, wherein the fragment comprises the sequence of SEQ ID NO;
34, a mutant of the extracellular water-soluble domain of DLK1, wherein the mutant comprises the sequence of SEQ ID NO;
34, or a fragment of the mutant, wherein the fragment comprises the sequence of SEQ ID NO;
34, as an active ingredient.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to a myostatin inhibitor comprising extracellular water-soluble domains of delta-like 1 homolog (DLK1) as active ingredients. More particularly, the present invention relates to a composition for inhibiting myostatin activity, comprising, as active ingredients, extracellular water-soluble domains of DLK1 or a deletion mutant of extracellular water-soluble domains of DLK1. The myostatin inhibitor of the present invention is bonded to the myostatin or activin receptor type IIB so as to inhibit the action mechanism of the myostatin, to thereby promote myogenesis and prevent differentiation into fat cells. Therefore, the myostatin inhibitor of the present invention may be used in preventing and treating diseases such as muscular dysplasia that requires differentiation to muscular cells, or metabolic diseases.
2 Citations
11 Claims
-
1. A method for treating a myostatin-related disease, comprising administering to a subject having a myostatin-related disease, an extracellular water-soluble domain of a delta-like 1 homolog (DLK1) comprising the sequence of SEQ ID NO:
- 34, a fragment of the extracellular water-soluble domain of DLK1, wherein the fragment comprises the sequence of SEQ ID NO;
34, a mutant of the extracellular water-soluble domain of DLK1, wherein the mutant comprises the sequence of SEQ ID NO;
34, or a fragment of the mutant, wherein the fragment comprises the sequence of SEQ ID NO;
34, as an active ingredient. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11)
- 34, a fragment of the extracellular water-soluble domain of DLK1, wherein the fragment comprises the sequence of SEQ ID NO;
Specification